Results 231 to 240 of about 778,750 (338)

Safety of sulfamethoxazole–trimethoprim for the treatment of bacterial infection in outpatient settings: A systematic review and meta‐analysis with active comparator disproportionality analysis

open access: yesBritish Journal of Clinical Pharmacology, EarlyView.
Aims Sulfamethoxazole–trimethoprim (SMX‐TMP) is a widely used antibiotic for treating bacterial infections, but its safety in adult outpatients remains understudied. This systematic review and meta‐analysis evaluated the safety profile of SMX‐TMP and identified critical research gaps.
Rebecca Preyra   +4 more
wiley   +1 more source

Drug–drug interaction profile of ritlecitinib as perpetrator and victim through cytochrome P450

open access: yesBritish Journal of Clinical Pharmacology, EarlyView.
Aims To assess the effect of a potent cytochrome P450 (CYP) 3A inhibitor and CYP inducer on the pharmacokinetics of ritlecitinib, a JAK3/TEC family kinase inhibitor, and assess the effect of ritlecitinib on the pharmacokinetics of CYP substrates (midazolam, efavirenz, tolbutamide, caffeine and oral contraceptives [ethinyl oestradiol and levonorgestrel])
Vivek S. Purohit   +6 more
wiley   +1 more source

A study of the cytochromes of Octopus vulgaris Lam [PDF]

open access: green, 1957
Anna Ghiretti‐Magaldi   +2 more
openalex   +1 more source

Metamizole induces voriconazole metabolism and results in subtherapeutic voriconazole concentrations

open access: yesBritish Journal of Clinical Pharmacology, EarlyView.
Aims Voriconazole is extensively metabolized via cytochrome P450 (CYP) enzymes, predominantly CYP2C19 and CYP3A4. Drugs influencing the activity or expression of CYP enzymes can cause clinically relevant changes in the metabolism and voriconazole exposure. Metamizole is known to induce CYP3A4 and CYP2C19.
Simone D. Baan   +3 more
wiley   +1 more source

Home - About - Disclaimer - Privacy